Identifying mutations in relapsed pediatric neuroblastoma may lead to better treatment options
the ONA take:
According to a new study published today in the journal Nature Genetics, researchers from various sites around the world have found that the majority of pediatric patients with relapsed neuroblastoma studied harbored mutations that promoted RAS-MAPK pathway signaling. Increased signaling in this pathway results in the progression of neuroblastoma.
"Our greater understanding of mutations on a crucial biological pathway offers prospects of acting on these pathways for direct benefit to children with this aggressive form of neuroblastoma," said senior author John M. Maris, M.D., a pediatric oncologist at The Children's Hospital of Philadelphia.
A class of drugs known as MEK inhibitors have demonstrated activity against this signaling pathway, suggesting that MEK inhibitors may benefit relapsed patients who possess mutations on the RAS-MAPK pathway.
Neuroblastoma is a solid tumor of the peripheral system that often grows in the chest or abdomen. It is the most common type of cancer in infants and is known for a high mortality rate in children. Most patients initially respond to chemotherapy, but many relapse and die from the disease.
Majority of pediatric patients with relapsed neuroblastoma studied harbored mutations that promoted RAS-MAPK pathway signaling.
Sign Up for Free e-newsletters
- Is Radioimmunotherapy a Path Forward for Melanoma?
- FDA Approves Mogamulizumab-kpkc for Rare Subtypes of Non-Hodgkin Lymphoma
- New PDL1 Inhibitors for Non-small Cell Lung Cancer: Focus on Pembrolizumab
- Intensive Chemotherapy May Not Be Effective in MDS or AML After MDS
- ASCO Endorses SIO Guideline for Integrative Therapies in Breast Cancer
- Seeking Reliable Information on Herbal Products
- NCCIH HerbList App Launched to Provide Information on Herbal Products
- Metformin Use May Improve Survival Outcomes in Bladder Cancer
- Higher Vitamin D Levels Associated With Lower Breast Cancer Risk
- Nurse-Led Program Improves Health, Financial Outcomes in Outpatient Chemotherapy
- Adhering to Cytoreductive Therapy Use May Improve Outcomes in Polycythemia Vera
- Disparities Remain in Prevalence of Cancer Screening Tests
- Hope, Gratitude, and Spirituality: What They Mean to Cancer Patients
- FDA, EU Approvals Sought for Split Dose Regimen of Daratumumab for Multiple Myeloma
- 8 Hours of Bedrest May Be Ideal After Intrathecal Chemotherapy in Hematologic Cancers
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|